CardioComm Solutions to Initiate Sales of the Heartcheck(TM) ECG Pen Device in Pharmacies Across Canada

From tmxmoney.com:

Toronto, Ontario--(Newsfile Corp. - February 2, 2015) - CardioComm Solutions, Inc. (TSXV :EKG) ("CardioComm Solutions" or the "Company") today announced that it has entered into an agreement with Shoppers Drug Mart Inc. ("Shoppers Drug Mart") for the over-the-counter ("OTC") sale of the HeartCheck™ ECG PEN device in pharmacies across Canada. The HeartCheck™ ECG PEN has passed regulatory reviews by both Health Canada and the US Food and Drug Administration as the only OTC ECG displaying device personal heart-health monitoring solution available without a physician's prescription.
The HeartCheck™ PEN will be made available in approximately 602 Shoppers Drug Mart Pharmacies by February 2015 which will coincide with the start of Heart Month. The product will be placed within the diabetes and high blood pressure monitoring devices section of the store planogram.
The HeartCheck™ PEN ECG can store 20 ECG recordings in memory which can be transferred to a computer for review and management. Consumers purchasing the device will have access to the Company's free GEMS™ Home software and a free first ECG interpretation through the CardioComm Solutions' SMART Monitoring ECG service. Sales will target those consumers, and their family, who are interested in the preservation of their heart health as well as those at risk for developing arrhythmias due to underlying conditions, especially prior heart attack, prior cardiac surgery, high blood pressure, high cholesterol, heart failure, diabetes and those taking medications that cause arrhythmias.
CardioComm Solutions has been working with pharmacy banner groups to expand introduction of ECG self-screening and monitoring into the consumer market. The HeartCheck™ PEN is as a groundbreaking and proven medical device that meets the pharmacies' objective of enhancing personalized heart-health monitoring and betterment of their customers' health.
More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company's web sitewww.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Grand Power Logistics Continues To Rise On More Insider Buying

GPW.V CURRENT PRICE: $0.065
GPW.V TARGET PRICE: $0.42
UPSIDE POTENTIAL: 546%
SHARES OUTSTANDING: 75,461,278
MARKET CAP: $4,904,983

January 13, 2015 - Since the alert from TSX Tech News And Analysis at the start of the year on Grand Power Logistics Group Inc.  (GPW.V), the stock has risen 18.5% from 5 cents to 6.5 cents. It has more than doubled from December lows of 3 cents, sparked by insider buying and a stock repurchase program. On December 29, GPW's CFO Alan Chan purchased 130,000 shares at 4 cents and followed that up with a 50,000 share purchase at 5 cents on January 8. Another insider purchased 200,000 shares at 6.5 cents during the summer according to CanadianInsider:



In December, the company authorized a share repurchase program of about 5% of the outstanding float or 3,773,000 shares, citing a strong cash balance and a belief that the shares are highly undervalued. The company has already repurchased and cancelled 502,000 shares according to the data above.

TSX Tech News And Analysis has a 42 cent target price on GPW. GPW has achieved a 2 cent EPS over the past year with 36% revenue growth so far for the nine months in 2014. According to GPW's stock quote on TMXMoney.com, the official stock quote site for TSX-listed stocks, GPW has a P/E Ratio of only 2.2 and a P/B Ratio of only 0.342 with much of that being in the form of cash.



Investors should expect a big move from GPW in 2015 because of the share repurchase program, strong revenue growth and very cheap multiples. With 502,000 shares purchased so far, the company still has 3,271,000 shares to repurchase on the open market.


Grand Power Logistics: A Stock With A Low P/E, A Share Repurchase Plan and Insider Buying

GPW.V CURRENT PRICE: $0.05
GPW.V TARGET PRICE: $0.42
UPSIDE POTENTIAL: 740%
SHARES OUTSTANDING: 75,461,278
MARKET CAP: $3,773,064

January 2, 2015 - Grand Power Logistics Group Inc.  (GPW.V) has risen from 3 cents to as high as 6 cents on heavy volume recently, sparked by insider buying and preparation for a stock repurchase program. On December 29, GPW's CFO Alan Chan purchased 130,000 shares at 4 cents, in addition to the 200,000 shares purchased by another insider at 6.5 cents during the summer according to CanadianInsider:


In December, the company authorized a share repurchase program of about 5% of the outstanding float or 3,773,000 shares, citing a strong cash balance and a belief that the shares are highly undervalued as reasons to undertake it. TSX Tech News And Analysis agrees with this assessment as it has a 42 cent target price on GPW. GPW has achieved a 2 cent EPS over the past year with 36% revenue growth so far for the nine months in 2014. At 5 cents, the P/E ratio for GPW is only 2.5.

Investors should expect a good 2015 from GPW because of the share repurchase program and strong revenue growth. At some point in time nearly 3.8 million shares will have to be purchased on the open market. GPW's Level 2 bids and asks point to a high price increase as there are currently 630,000 shares on the bid between 3 and 5 cents but only 159,000 on the ask side at 10 cents or below. At any point in time the company could decide to make its first purchase of shares and take the stock price to 10 cents. Investors have the added bonus of a safety net if they buy shares now. Since they know that the company will be purchasing shares, there will be enough liquidity on the bid side to ensure that they can sell the stock at a good price should they need to do so at some point in time during 2015.


Delayed Market Depth By Price Summary

Last Market by Price Update: 02 Jan 2015 11:29 ET

Instrument Name: Grand Power Logistics Group Inc.      Symbol: GPW
The market data displayed is provided on a 15-minute delayed basis and we do not guarantee its accuracy or completeness. Please refer to the date/time stamp above to obtain the age of the data in this table.
BID
OrdersVolumePrice Range
23630,0000.03000-0.05000
ASK
Price RangeVolumeOrders
0.05500-0.10000159,00010



Grand Power Logistics Group Inc. Announces Plans to Repurchase Common Shares

From tsx.com:

CALGARY, ALBERTA--(Marketwired - Dec. 8, 2014) - Grand Power Logistics Group Inc. (the "Corporation" or "Grand Power") (TSX VENTURE:GPW) announces that it has filed with the TSX Venture Exchange a Notice of Intention to Make a Normal Course Issuer Bid which shall commence on December 8, 2014 and terminate on December 7, 2015 or the earlier of the date that all shares which are subject to the Normal Course Issuer Bid are purchased.
In the opinion of the Board of Directors of Grand Power, the market price of the Common Shares of Grand Power does not accurately reflect the value of those shares. As a result, the Corporation intends to repurchase Grand Power's Common Shares that may become available at purchase prices which make the purchases an appropriate use of the funds of the Corporation.
Grand Power intends to attempt to acquire up to an aggregate of 3,773,000 of its Common Shares over the next 12-month period, representing approximately 5% of the issued and outstanding Common Shares of Grand Power.
Purchases subject to the Normal Course Issuer Bid will be carried out pursuant to open market transactions through the facilities of the TSX Venture Exchange. The Member through which the Normal Course Issuer Bid will be conducted is Wolverton Securities, Calgary, Alberta. All Common Shares purchased by Grand Power under the Normal Course Issuer Bid will be cancelled.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Grand Power Logistics Group Inc.
Alan P. Chan
Secretary and Chief Financial Officer
(403) 228-3013
(403) 237-8211
alanchan@grandpowerlogistics.com

Grand Power Logistics Reports Excellent Q2 2014 Results

GPW.V CURRENT PRICE: $0.065
GPW.V TARGET PRICE: $0.42
UPSIDE POTENTIAL: 546%
SHARES OUTSTANDING: 75,461,278
MARKET CAP: $4,904,983
WORKING CAPITAL: $2,900,000

August 29, 2014 - Grand Power Logistics Group Inc.  (GPW.V) reported its Q2 results on SEDAR on Friday. From the MD&A:

"Sales revenue for the three months ended June 30, 2014 increased by $7,066,266 (52.67%) to $20,481,130 from $13,414,864 in 2013. The increase in sales revenue is primarily due to the unexpected improvement in air freight business in the Corporation’s Hong Kong division and the increase in ocean freight business. Gross profit for the three months ended June 30, 2014 increased by 71.77% to $1,707,677 compared to $994,145 in 2013, and gross profit margin increased to 8.34% compared to 7.41% for 2013. The increase in gross profit is primarily due to the increase in revenue.

The income from operations for the three months ended June 30, 2014 increased by 162.3% to $378,570 compared to a loss of $607,229 for 2013. The improvement is primarily due to a higher gross profit and a decrease in general operating expenses. General operating expenses for the three months ended June 30, 2014 decreased by 17.00% to $1,329,107 compared to $1,601,374 in 2013 despite the significant increase in sales revenue. The decrease in corporate operating expenses was primarily due to the decrease in general and administrative expenses as the Corporation continues to reduce its overhead expenses.

The net loss for the three months ended June 30, 2014 was $87,188 compared to a net profit of $485,959 in 2013. The net loss attributable to the owners of the Corporation for the three months ended June 30, 2014 was $87,191 compared to a net profit of $480,115 in 2013. The decrease in net profit was principally due to the decrease of the Company’s share of equity value in associated companies in the amount of $416,881. Without accounted for this equity value, the Company would have a net profit of $329,693."

The company showed strong growth in revenue and operating profit. The bottom line was negatively impacted thanks to the loss in equity value in its associated companies, which has traditionally been a positive mover for the company. Posted below are the last eight quarters of financial results from Page 6 of GPW's MD&A so we get a good sense of where they have been headed.


We can see that Q2 2014 is the second highest period for revenue out of the last eight quarters and the best when it comes to gross profit so the company has been on the right track. Even when ignoring the very good revenue growth for the past three quarters, GPW is clearly quite undervalued. The market cap is $4.9 million and the share price is 6.5 cents. The last four quarters have seen over $73 million in gross revenue with an EPS of 2.1 cents. GPW's price to earnings ratio is only 3 and the price to sales ratio is a minuscule 0.07, easily one of the lowest on the TSX, especially for a company with a positive working capital and good revenue growth.

Year over year revenue growth has been a strong 21.7% and annual gross profits were $5.6M compared to $4.6M in the previous four quarters for a growth rate of 22.7%. With these types of results we should expect a target P/E ratio of at least 20, or 42 cents a share. 42 cents per share would result in a market cap of $31.7M or a very low 0.43 price to sales ratio.

As a comparison, Fireswirl Technologies (FSW.V) has achieved $49.1M in revenue for the past four quarters with a $9.6M market cap so that company has a very low price to sales ratio of only 0.2 but that's still three times higher than GPW's price to sales ratio. FSW continues to have net losses and has a revenue growth rate of 30.1% for Q2 2014 and 17.9% for the first half of 2014, inferior to GPW's 52.7% growth rate for Q2 and 40.6% for the first half of 2014. GPW is a highly undervalued stock to watch for the remainder of 2014.

Management appears to agree that the stock price is undervalued as one member purchased 300K shares over the summer at 6.5 cents according to CanadianInsider:


Biotech Company Comes Back To Life After Positive Study Results

ICO.V CURRENT PRICE: $0.07
ICO.V TARGET PRICE: $0.20
UPSIDE POTENTIAL: 186%
SHARES OUTSTANDING: 84,457,713
MARKET CAP: $5,912,040
WORKING CAPITAL (FROM Q1 2014): $4,863,860

August 19, 2014 - iCo Therapeutics Inc. (ICO.V) rose 40% to 7 cents on over 17 million shares traded today after the company announced positive Oral Amphotericin B Study results on the treatment of HIV. From the release:

"There are a number of HIV latent reservoirs that are not inducible and our partners at ImmuneCarta were pleasantly surprised that six of the seven samples had inducible latent reservoirs in our study," said Dr. Peter Hnik, Chief Medical Officer of iCo Therapeutics.  "By turning on expression of latent HIV proviruses, reactivation strategies such as Oral Amp B, could contribute to a reduction of HIV infection.  Given these promising results, we are now evaluating the next steps in the developmental path for Oral Amp B."

While the sample size of 7 patients is small, the news that this therapy could reduce the risk of HIV infection has brought back life into this company after the stock price got hammered in June following the disappointing results of the iCo-007 Phase 2 iDEAL Study for Diabetic Macular Edema. ICO is trading below its working capital and investment holding value so investors realized that even with a small study, these results warrant giving substantially more value to ICO's pipeline. Even though iCo-007 has disappointed thus far, it, Oral Amphotericin B and iCo-008 deserve some market value for the potential that they hold.

ICO's value can be split into three distinct categories:


Working capital was $4.9M according to Q1 results ended March. Assuming a cash burn rate of $1M for the quarter, we can estimate working capital will be $3.9M or 4.6 cents per share.

ICO holds shares in IMNP, pictured below from the Q1 MD&A:


IMNP closed at $4 today so the 654K shares lead to $2.62M US in value. The warrants have a strike price of $2.63 so ignoring all time value that leads to an intrinsic value of $1.37 or $0.17M US in value for a total of $2.79M US or about $3M Canadian. The holdings in IMNP are worth 3.5 cents per share for ICO. There is great potential for the value in these shares to rise as IMNP is listing on the NASDAQ this week, is seeking analyst coverage and has several ongoing Phase 2/3 Trials, including the ones for Bertilimumab (iCo-008) .


With Amiket and Crolibulin at more advanced stages, IMNP doesn't even need to succeed with Bertilimumab to provide ICO shareholders with upside potential. If IMNP were to increase to $10, ICO's investment in IMNP would be worth 9.5 cents on its own. If IMNP were to reach $20, the value to ICO would be 19.5 cents per share. Any success with the iCo-008 (Bertilimumab) Phase II clinical trial in patients with ulcerative colitis will provide investment gains on IMNP and immeditate increased value to iCo-008 based on its chance of successful treatment of one ailment, leading to a higher possibility that it can treat more.

The largest value potential is ICO's product pipeline. Prior to the disappointing results on iCo-007, Zack's Investment Research had a 90 cent target on ICO, broken down by parts:


Zack's has since released a 15 cent target based on writing off all value for iCo-007. The firm believes ICO has $17.5M in value but uses the fully diluted share count of 115 million to lead to the 15 cent target. The majority of the options and warrants have strike prices above 50 cents. If they were to be exercised they would bring additional cash to the company. But it is fair to assume that at 7 cents, exercise of the options and warrants are not imminent and it is fairer to divide the $17.5M market cap estimate by 84.46M shares to lead to a 20 cent target.

Based on the low share price, TSX Tech News And Analysis believes that further license agreements similar to the one with IMNP is the best course of action to maximize shareholder value at these prices while conserving cash. If  iCo-008 and  iCo-009 have $35M in value, let's assume a partnership deal would leave ICO with a 25% stake in both of them. $35M x 25% is $8.75M or about 10 cents per share.

Reviewing:
  • Working capital: 4.6 cents per share
  • Value of holdings in IMNP: 3.5 cents per share
  • Value of the pipeline: 10 cents per share

TSX Tech News And Analysis is aligned with Zack's 20 cent target on ICO. If IMNP continues to successfully advance Bertilimumab or another one of the drugs in their pipeline it could be much higher than that.

iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

From tsx.com:

VANCOUVERAug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.  The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.
Memory cells, or white blood cells, from eight HIV-infected subjects with a durable viral suppression using antiretroviral therapy (HAART) were obtained and exposed in vitro to various concentrations of Oral Amp B. Samples from one  patient were determined not to be susceptible to reactivation.  In the remaining subjects, Oral Amp B demonstrated a reactivation response of HIV viral production in six out of seven in vitro cultures with detectable HIV reservoir.  Some HIV reservoirs are not possible to reactivate and this may explain why one culture did not show reactivation response.
"There are a number of HIV latent reservoirs that are not inducible and our partners at ImmuneCarta were pleasantly surprised that six of the seven samples had inducible latent reservoirs in our study," said Dr. Peter Hnik, Chief Medical Officer of iCo Therapeutics.  "By turning on expression of latent HIV proviruses, reactivation strategies such as Oral Amp B, could contribute to a reduction of HIV infection.  Given these promising results, we are now evaluating the next steps in the developmental path for Oral Amp B."
About iCo Therapeutics iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF". For more information, visit the Company website at:www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking Statements Certain statements included in this press release may be considered forward-looking statements" within the meaning of applicable securities laws.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will," and similar references to future periods and includes, but is not limited to, statements about the intended use of proceeds of the Offering. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.